3.24
-0.02 (-0.61%)
| Previous Close | 3.26 |
| Open | 3.27 |
| Volume | 2,155,000 |
| Avg. Volume (3M) | 3,852,583 |
| Market Cap | 3,113,756,672 |
| Price / Sales | 11.22 |
| Price / Book | 1.88 |
| 52 Weeks Range | |
| Earnings Date | 15 Aug 2024 |
| Profit Margin | -84.27% |
| Operating Margin (TTM) | -49.79% |
| Diluted EPS (TTM) | -0.250 |
| Quarterly Revenue Growth (YOY) | 27.20% |
| Total Debt/Equity (MRQ) | 20.05% |
| Current Ratio (MRQ) | 4.61 |
| Operating Cash Flow (TTM) | -175.20 M |
| Levered Free Cash Flow (TTM) | -123.30 M |
| Return on Assets (TTM) | -7.97% |
| Return on Equity (TTM) | -12.41% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (HK) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | ALPHAMAB-B | - | - |
AIStockmoo Score
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 3.5 |
| Technical Oscillators | -2.5 |
| Average | -0.25 |
Similar Stocks
| Stock | Market Cap | DY | P/E (TTM) | P/B |
|---|---|---|---|---|
| ALPHAMAB-B | 3 B | - | - | 1.88 |
| LEPU BIO-B | 5 B | - | - | 4.75 |
| FRONTAGE | 3 B | - | 83.00 | 1.29 |
| ABBISKO-B | 3 B | - | - | 1.21 |
| CSTONE PHARMA-B | 3 B | - | - | 5.94 |
| GENOR-B | 930 M | - | - | 0.800 |
|
Alphamab Oncology is a clinical-stage biopharmaceutical company in China with a fully integrated proprietary biologics platform in bispecifics and protein engineering. The company through its subsidiaries is engaged in the discovery, development manufacturing, and commercialization of biotherapeutics for cancer treatment. Its product pipeline includes various drug candidates such as KN035 (Envida), KN046, KN026, JSKN003, and KN019 among others in different stages of development. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 51.05% |
| % Held by Institutions | 4.61% |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |